Investors of Silk Road Medical have expressed concerns about the competitive risk to the company's TCAR procedure due to CMS reconsidering its coverage restrictions for carotid artery stenting. However, it is unlikely that CMS will create full coverage parity between these procedures in its upcoming proposal.
Policy & Legal, Research
Silk Road (SILK): Competition & Coverage
17 April 2023
Summary
Want to learn more? Download the Report.
Solutions
Public Policy & Legal Research
Identify opportunity and risk driven by public policy and the courts.
Forensic Accounting Research
Understand implications of public company financial reporting.